Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model

Breast Cancer Research

Table 1 p-EGFR expression status in tumor and stroma of IBC patient samples

	p-EGFR expression status in tumor: No. of patients (%)			p-EGFR expression status in stroma: No. of patients (%)
	Negative	Positive	P	Negative	Positive	P
ER expression
Negative	5 (22.7)	17 (77.3)	0.279	1 (4.2)	23 (95.8)	0.810
Positive	4 (22.2)	14 (77.8)		0 (0.0)	19 (100.0)
PR expression
Negative	4 (17.4)	19 (82.6)	0.304	1 (3.8)	25 (96.2)	0.778
Positive	5 (29.4)	12 (70.6)		0 (0.0)	17 (100.0)
HER2 expression
Negative	8 (28.6)	20 (71.4)	0.226	1 (3.6)	27 (96.4)	0.337
Positive	0 (0.0)	8 (100.0)		0 (0.0)	10 (100.0)
Triple-negative status
No	5 (18.5)	22 (81.5)	0.484	0 (0.0)	29 (100.0)	0.329
Yes	3 (33.3)	6 (66.7)		1 (11.1)	8 (88.9)

p-EGFR, phospho-epidermal growth factor receptor; IBC, inflammatory breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

ISSN: 1465-542X